Skip to main content

Table 3 Two-year death rates according to patients' characteristics and exposure to revascularization and medication (n = 5596)

From: Revascularization and cardioprotective drug treatment in myocardial infarction patients: how do they impact on patients' survival when delivered as usual care

  Total 2-year CV death 2-year non-CV death
Total 5596 603 (10.8%) 525 (9.4%)
Mean Age ± SD 5596 79.3 ± 7.3 77.0 ± 7.4
Gender    
Women 2390 291 (12.2%)a 215 (9.0%)d
Men 3206 312 (9.7%) 310 (9.7%)
Comorbidity index    
   Mean ± SD (median) 5596 2.6 ± 1.9 (2) 2.6 ± 2.1 (2)
   0 2012 83 (4.1%)b 89 (4.4%)b
   1–2 2077 227 (10.9%) 188 (9.0%)
   3–4 1111 197 (17.7%) 152 (13.7%)
   5–6 318 77 (24.2%) 72 (22.6%)
   ≥ 7 78 19 (24.4%) 24 (30.8%)
Revascularization    
   No 4473 567 (12.7%)c 478 (10.7%)c
   Yes 1123 36 (3.2%) 47 (4.2%)
PTCA 767 24 (3.1%)d 33 (4.3%)d
CABG 356 12 (3.4%) 14 (3.9%)
Number of drug classes    
   0 757 117 (15.5%)e 113 (14.9%)e
   1 1166 162 (13.9%) 136 (11.7%)
   2 2046 207 (10.1%) 178 (8.7%)
   3 1315 103 (7.8%) 78 (5.9%)
   4 312 14 (4.5%) 20 (6.4%)
  1. a The difference in CV death and in non-CV death rates between genders is statistically significant (p = .0003)
  2. b The difference in CV death and in non-CV death rates between Comorbidity index groups is statistically significant (p < 0.0001)
  3. c The difference in CV death and in non-CV death rates according to presence/absence of revascularization is statistically significant (p < 0.0001)
  4. d The difference in CV death and in non-CV death rates according to PTCA or CABG is not statistically significant (p > 0.05)
  5. e The difference in CV death and in non-CV death rates according to number of drugs classes claimed is statistically significant (p < 0.0001)